Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3862995B in adults with bronchiectasis
2025-522892-27-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing GSK3862995B with Placebo (2 arms). Primary endpoint: Percentage reduction in annualized exacerbation rate. Planned start Mar 2026; status: authorised.
02
Drugs
gsk3862995b
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2025-522892-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522892-27-00.